Christine Thomas
About Christine Thomas
Christine Thomas is Chief Regulatory & Clinical Officer at Femasys Inc. (FEMY), serving since October 2022; she is 52 and brings 20+ years of regulatory and clinical leadership across major med-techs, with prior roles at GE Healthcare, Boston Scientific, Smiths Medical, RTI Surgical, and consulting at IQVIA; she holds a BS in Education (University of Wisconsin–Whitewater) and is in a Johns Hopkins MS program . Company performance during her tenure shows revenues increased year-over-year while losses widened; Femasys also adopted a Dodd-Frank/Nasdaq-compliant clawback for executive incentive compensation and maintains an insider trading policy without a standalone anti-hedging policy .
Company performance metrics:
| Metric | FY 2023 | FY 2024 |
|---|---|---|
| Revenue ($USD) | $1,071,970 | $1,629,108 |
| EBITDA ($USD) | -$14,024,934* | -$17,488,487* |
| Net Income ($USD) | -$14,247,124* | -$18,816,628* |
*Values retrieved from S&P Global via GetFinancials.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| GE Healthcare | Regulatory/Clinical leadership roles | Not disclosed | Global regulatory strategy and clinical operations leadership |
| Boston Scientific | Regulatory/Clinical leadership roles | Not disclosed | Regulatory, quality, design assurance and compliance leadership |
| Smiths Medical | Regulatory/Clinical leadership roles | Not disclosed | Led regulatory, quality, clinical, and compliance functions |
| RTI Surgical | Regulatory/Clinical leadership roles | Not disclosed | Led FDA-facing regulatory and clinical activities |
| IQVIA (consulting) | FDA-focused consultant | Not disclosed | Regulatory and clinical consulting on FDA processes |
External Roles
No public company directorships or external board roles disclosed for Christine Thomas .
Fixed Compensation
Individual base salary, target bonus %, and actual bonus paid for Christine Thomas are not disclosed (she is not a Named Executive Officer in FEMY’s proxies) .
Performance Compensation
Specific RSU/PSU grants, option awards, performance metrics, weightings, targets, and payouts for Christine Thomas are not disclosed (non-NEO). Company-wide plan mechanics permit awards tied to goals including regulatory milestones, TSR, EBITDA, revenue, margins, and market share, with clawback and no option repricing without shareholder approval .
Equity Ownership & Alignment
- Beneficial ownership for Christine Thomas is not itemized in the security ownership tables (tables list 5% holders, directors, and NEOs) .
- Company policies:
- Clawback: Executive incentive compensation subject to recoupment upon material restatement under Dodd-Frank/Nasdaq .
- Insider trading policy: Applies to executives, employees, and directors; Femasys does not have a standalone anti-hedging policy .
- Section 16 compliance: One late Form 4 filing was noted for Ms. Thomas (transaction 10/10/2023; filed 11/1/2023) .
Employment Terms
No employment agreement, severance, or change-of-control terms are disclosed for Christine Thomas. The CEO/CFO/COO employment terms and severance multiples are disclosed for comparison, but do not apply to Thomas absent specific documentation .
Performance & Track Record
- Role scope: As Chief Regulatory & Clinical Officer since Oct 2022, her tenure coincides with multiple regulatory milestones including:
- FemBloc delivery system approval in Europe and significant commercialization steps (Mar 13, 2025) .
- UK regulatory approval for FemBloc (Aug 20, 2025) .
- Australian and New Zealand approvals (Jul 1, 2025) .
- Initiation of EU post-market surveillance clinical study for FemBloc (Oct 22, 2025) .
- Company framing: Femasys highlights Thomas’s 25+ years of global regulatory strategy and clinical operations leadership as part of an experienced team advancing women’s health solutions .
Compensation Committee Analysis
- Committee composition: Independent directors oversee executive and equity comp; ability to appoint and oversee compensation consultants .
- Equity plan governance: 2021 Plan prohibits repricing underwater options/SARs without shareholder approval; change-in-control mechanics include conditional acceleration if not assumed and double-trigger protections in certain cases .
- Share pool expansion: 2025 proxy sought an increase of 3,000,000 shares for the 2021 Plan (to 6,858,597 total) to support talent attraction/retention with equity .
Investment Implications
- Alignment and retention: Thomas’s senior regulatory role and tenure through major approvals suggest continuity in FEMY’s regulatory execution; however, lack of disclosed individual compensation/ownership limits visibility into pay-for-performance alignment and retention economics for this executive .
- Policy signals: Presence of a robust clawback is shareholder-friendly; absence of a standalone anti-hedging policy is a modest alignment gap, and one late Form 4 suggests minor administrative risk but no material red flag by itself .
- Equity overhang and future supply: Approved expansion of the equity plan points to continued equity-heavy compensation; while positive for cash conservation, it can create future selling pressure at vesting, though specific tranches for Thomas are not disclosed .
- Execution risk vs. value creation: Company revenues grew FY23→FY24 while losses widened, underscoring the importance of regulatory-driven commercialization under Thomas’s remit; continued regulatory milestones across geographies support potential revenue scaling but profitability timing remains uncertain (see table above) .* Values for EBITDA and Net Income retrieved from S&P Global.